Cost effectiveness analysis of a hypertension management program in patients with type 2 diabetes

Journal of Clinical Hypertension

Volumn 11, Issue 3, 2009, Pages 116-124

  Ly, David ^a   Alex, Fu Z ^b   Christopher, Hebert ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC HYPERTENSION; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INCIDENCE; INVESTMENT; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SENSITIVITY ANALYSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MARKOV CHAINS; MIDDLE AGED; PATIENT CARE; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63349099339     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00082.x     Document Type: Article

References (41)

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the united states 1999 to 2000: A rising tide. Hypertension. 2004;44:398-404.
2. Chobanian AV, Bakris GL, Black HR, et.al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
4. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. JAMA. 2003;289:2083-2093.
5. Artinian NT, Flack JM, Nordstrom CK, et al. Effects of nurse-managed telemonitoring on blood pressure at 12-month follow-up among urban african americans. Nurs Res. 2007;56:312-322.
6. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA. 2006;296:2563-2571.
7. Petrella RJ, Koval JJ, Cunningham DA, et al. Can primary care doctors prescribe exercise to improve fitness? The step test exercise prescription (STEP) project. Am J Prev Med. 2003;24:316-322.
8. Roumie CL, Elasy TA, Greevy R, et al. Improving blood pressure control through provider education, provider alerts, and patient education: A cluster randomized trial. Ann Intern Med. 2006;145:165-175.
9. Rudd P, Miller NH, Kaufman J, et al. Nurse management for hypertension. A systems approach. Am J Hypertens. 2004;17:921-927.
10. Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 2000;160:1277-1283.
11. UK prospective diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
12. CDC diabetes cost-effectiveness group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542-2551.
13. Mitka M. Many physician practices fall short on accurate blood pressure measurement. JAMA. 2008;299:2842-2844.
14. Houweling ST, Kleefstra N, Lutgers HL, et al. Pitfalls in blood pressure measurement in daily practice. Fam Pract. 2006;23:20-27.
15. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334:885.
16. Paschal AM, Lewis RK, Martin A, et al. Evaluating the impact of a hypertension program for african americans. J Natl Med Assoc. 2006;98:607-615.
17. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
18. U.K. prospective diabetes study group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-1136.
19. Menard J, Payette H, Dubuc N, et al. Quality of life in type 2 diabetes patients under intensive multitherapy. Diabetes Metab. 2007;33:54-60.
20. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
22. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339:861-867.
23. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study (ARTS) trial. Circulation. 2001;104:533-538.
24. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med. 2006;166:112-118.
25. Brown DL, Boden-Albala B, Langa KM, et al. Projected costs of ischemic stroke in the united states. Neurology. 2006;67:1390-1395.
26. Kaul P, Armstrong PW, Cowper PA, et al. Economic analysis of the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction. Am Heart J. 2005;149:637-644.
27. Matas AJ, Schnitzler M. Payment for living donor (vendor) kidneys: A cost-effectiveness analysis. Am J Transplant. 2004;4:216-221.
28. Wexler DJ, Grant RW, Wittenberg E, et.al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49:1489-1497.
29. Mathias SD, Bates MM, Pasta DJ, et al. Use of the health utilities index with stroke patients and their caregivers. Stroke. 1997;28:1888-1894.
30. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583-637.
31. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke. 2001;32:964-972.
32. Kasper EK, Gerstenblith G, Hefter G, et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol. 2002; 39:471-480.
33. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83:890-896.
34. Emanuel EJ, Ash A, Yu W, et al. Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med. 2002;162:1722-1728.
35. Hoover DR, Crystal S, Kumar R, et al. Medical expenditures during the last year of life: Findings from the 1992-1996 medicare current beneficiary survey. Health Serv Res. 2002;37:1625-1642.
36. Levinsky NG, Yu W, Ash A, et al. Influence of age on medicare expenditures and medical care in the last year of life. JAMA. 2001;286:1349-1355.
37. Lee WC, Christensen MC, Joshi AV, et al. Long-term cost of stroke subtypes among medicare beneficiaries. Cerebrovasc Dis. 2007;23:57-65.
38. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115:2398-2409.
39. Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA. 2003;290:3101-3114.
40. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611-622.
41. Mohr PE, Neumann PJ, Franco SJ, et al. The case for daily dialysis: Its impact on costs and quality of life. Am J Kidney Dis. 2001;37:777-789.